Zobrazeno 1 - 10
of 353
pro vyhledávání: '"J.-P Bassand"'
Autor:
C Escobar Cervantes, A J Camm, S Virdone, K A A Fox, J P Bassand, K Pieper, G Kayani, A K Kakkar
Publikováno v:
European Heart Journal. 43
Background Atrial fibrillation (AF) is associated with a significant increase in stroke risk. Anticoagulation (AC) guidelines recommend stratification of stroke risk to aid AC choice. However, despite evidence supporting AC, the associated bleeding r
Autor:
Freek W.A. Verheugt, Garfield-Af Investigators, Samuel Z. Goldhaber, K.A.A Fox, Alan John Camm, J.-P Bassand, Shinya Goto, A.G.G Turpie, Werner Hacke, Karen S. Pieper, Frank Misselwitz, Frank Cools, Gloria Kayani, Saverio Virdone, Sylvia Haas, Ajay K. Kakkar
Publikováno v:
European Heart Journal. 42
Introduction Diabetes mellitus (DM) is one of the most common comorbidities observed in patients with atrial fibrillation (AF). It is associated with increased risks of stroke/SE and death. Purpose To assess the impact of NOAC and VKA on outcomes of
Autor:
Karen S. Pieper, Samuel Z. Goldhaber, A.G.G Turpie, Shinya Goto, K.A.A Fox, Alan John Camm, Sylvia Haas, Ajay K. Kakkar, David Fitzmaurice, J.C.L Himmelreich, Frank Misselwitz, Saverio Virdone, J.-P Bassand, Freek W.A. Verheugt, Garfield-Af Investigators, Gloria Kayani
Publikováno v:
European Heart Journal. 42
Introduction Large phase III trials of non-valvular atrial fibrillation (AF) patients have shown a favourable risk-to-benefit ratio with Non-Vitamin K antagonist oral anticoagulants (NOAC) compared to Vitamin K antagonists (VKA). Although the results
Autor:
Karen S. Pieper, Garfield-Af Investigators, J.C.L Himmelreich, A.G.G Turpie, Alan John Camm, Samuel Z. Goldhaber, Ajay K. Kakkar, Sylvia Haas, J.-P Bassand, K.A.A Fox, Shinya Goto, Frank Misselwitz, Saverio Virdone, David Fitzmaurice, Ralf E. Harskamp, Freek W.A. Verheugt
Publikováno v:
European Heart Journal. 42
Introduction Generalisability of patient selection in the landmark trials for the approval of apixaban (ARISTOTLE) and rivaroxaban (ROCKET AF) for use in non-valvular atrial fibrillation (AF) is limited. Although observational data have confirmed the
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ajay K. Kakkar, Gloria Kayani, Garfield-Af Investigators, Frank Cools, Sylvia Haas, K.A.A Fox, Alan John Camm, Shinya Goto, J.-P Bassand, F. W. A. Verheugt, David W. Johnson, Karen S. Pieper, A.G.G Turpie, Samuel Z. Goldhaber, Frank Misselwitz, David Fitzmaurice
Publikováno v:
European Heart Journal. 41
Background Non-Vitamin K Antagonists (NOAC) are replacing vitamin K Antagonists (VKA) as first line oral anticoagulant therapy (OAC) in patients with non-valvular atrial fibrillation (NVAF). Discontinuation of OAC might put patients at increased risk
Autor:
A.G.G Turpie, Ajay K. Kakkar, David Fitzmaurice, J.-P Bassand, Frank Misselwitz, Samuel Z. Goldhaber, Alan John Camm, Gloria Kayani, Shinya Goto, Freek W.A. Verheugt, Garfield-Af Investigators, Sylvia Haas, Karen S. Pieper, Jan Steffel, Saverio Virdone, K.A.A Fox
Publikováno v:
European Heart Journal. 41
Introduction The GARFIELD-AF registry is a prospective, multicentre, observational study of adults with recently diagnosed non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. In GARFIELD-AF the absolute risk reduction of mo
Autor:
Shinya Goto, Ajay K. Kakkar, K.A.A Fox, Gloria Kayani, Karen S. Pieper, David Fitzmaurice, Freek W.A. Verheugt, Saverio Virdone, Sylvia Haas, Garfield-Af Investigators, J.-P Bassand, Frank Misselwitz, Alan John Camm, Patricia N. Apenteng, A.G.G Turpie, Samuel Z. Goldhaber
Publikováno v:
European Heart Journal. 41
Introduction Atrial fibrillation (AF) remains a common cause of stroke and anticoagulation (AC) treatment reduces the risk of stroke. Reasons for patients with AF not receiving anticoagulation are generally attributed to the clinician decision, howev
Autor:
Frank Cools, Gloria Kayani, J.-P Bassand, A. K. Kakkar, Saverio Virdone, Karen S. Pieper, S Verstraete
Publikováno v:
European Heart Journal. 40
Background Haematuria in atrial fibrillation (AF) patients taking oral anticoagulants (OACs) is usually viewed as less serious than intracranial and gastrointestinal bleeding. It is speculated that haematuria may result from renal excretion of active
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.